Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 15/20 | 0.48 |
| ▸ | HTR1A | P08908 | 10/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15981159 | 0.86 | DHFR (0.41) | HTR7HTR1ADHFRDRD2DRD3 | |
| SCHEMBL22085 | 0.84 | CYP1A2 (0.59) | HTR7HTR1AHPGD | |
| SCHEMBL19410718 | 0.83 | HTR7 (0.46) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL7167351 | 0.80 | HTR2A (0.47) | HTR7HTR1ADHFRDRD2DRD5 | |
| SCHEMBL14707083 | 0.80 | HTR2A (0.47) | HTR7HTR1ADHFRDRD2DRD5 | |
| SCHEMBL14707008 | 0.80 | HTR2A (0.47) | HTR7HTR1ADHFRDRD2DRD5 | |
| SCHEMBL29043141 | 0.78 | TSHR (0.55) | DRD4 | |
| SCHEMBL30685866 | 0.77 | OPRM1 (0.46) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL18781371 | 0.76 | OPRL1 (0.61) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL18781369 | 0.76 | OPRL1 (0.61) | HTR7HTR1ADRD2DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9611257-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611257-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9365555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. | 2016-06-14 | — | — | US | disclosed |
| US-9365555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. | 2016-06-14 | — | — | US | disclosed |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014100764-A2 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100716-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | PRMT5, PRMT1, PRMT7 | HTR7 4183/4885HTR1A 4369/4885DHFR 1527/4885 |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HTR7 4142/4885HTR1A 4598/4885DHFR 986/4885 |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HTR7 4142/4885HTR1A 4598/4885DHFR 986/4885 |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HTR7 4231/4885HTR1A 4485/4885DHFR 1022/4885 |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HTR7 4231/4885HTR1A 4485/4885DHFR 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.